Hans Biomed Corp (042520)

Currency in KRW
8,850
+640(+7.80%)
Closed·

042520 Financial Summary

Key Ratios

P/E Ratio-17.59
Price/Book1.79
Debt / Equity66.24%
Return on Equity-10.22%
Dividend Yield0.00%
EBITDA6.01B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
30/09
2016
30/09
2017
30/09
2018
30/09
2019
30/09
2020
30/09
2021
30/09
2022
30/09
2023
30/09
2024
30/09
* In Millions of KRW (except for per share items)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
64.00 / --
Revenue / Forecast
24.16B / --
EPS Revisions
Last 90 days

FAQ

What were Hans Biomed's earnings for the latest quarter?

The Hans Biomed EPS (TTM) is -510.64. Hans Biomed reported sales of 24,155.17, net income of 832.50, and EPS of 64.00 for the latest quarter.

What was Hans Biomed's net income for the latest quarter?

Hans Biomed's net income for the latest quarter was 832.50.

How did Hans Biomed's performance compare year-over-year in the latest quarter?

The company's revenue moved from 19,876.13 in the previous quarter to 24,155.17 in the latest quarter, and net income moved from -1,306.44 to 832.50 compared to the previous quarter.

What is Hans Biomed's net profit margin on a TTM basis?

Hans Biomed's trailing twelve months (TTM) net profit margin is -8.90%.

How does Hans Biomed's debt to equity ratio compare to industry standards?

Hans Biomed's total debt-to-equity ratio is 66.24%.

What is Hans Biomed's return on investment on a TTM basis?

Hans Biomed's trailing twelve months (TTM) return on investment (ROI) is -10.22%.

Did Hans Biomed gain or lose cash last quarter?

In the latest quarter, Hans Biomed's net change in cash was 6,208.16 million.

What were Hans Biomed's total assets and liabilities in the latest quarter?

As of the latest quarter, Hans Biomed reported total assets of 128,596.30 million and total liabilities of 53,571.00 million.

How has Hans Biomed's total revenue grown this year?

Hans Biomed's total revenue was 19,876.13 in the previous quarter and 24,155.17 in the latest quarter.

What is Hans Biomed's gross margin on a TTM basis?

Hans Biomed's trailing twelve months (TTM) gross margin is 62.30%.

What was Hans Biomed's revenue per share for the latest quarter?

Hans Biomed's revenue per share for the latest quarter was 2,934.85.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.